Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026.